Penumbra Inc. (PEN)
NYSE: PENHealthcareMedical DevicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 316.35 0.00%
PEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.46B
- P/E (TTM)
- 77.73
- Forward P/E
- 51.59
- EPS (TTM)
- $4.07
- Dividend yield
- None
- 52-week range
- 221.26 – 362.41
- Day range
- 316.33 – 317.74
- Volume / Avg
- 366.19K / 343.03K
- Beta
- —
- Shares outstanding
- 39.39M
- Next earnings
- Nov 4, 2026
52-week range
PEN stock today
Shares of Penumbra (PEN) finished lower on Oct 7 at $316.35, a drop of 0.22% or $0.70 per share, versus the S&P 500's 0.22% decline. Shares are 12.7% below their 52-week high of $362.41, set on Jan 21, 2026 and 43.0% above the 52-week low of $221.26, in the middle of the past year's range. PEN is up 2.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 27.3%.
At 77.7x trailing earnings, Penumbra trades above the peer-group median of 21.5x. Its forward P/E of 51.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Penumbra's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Penumbra
Company profilePenumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands.
- Sector
- Healthcare
- Industry
- Medical Devices
- CEO
- Mr. Adam Elsesser J.D.
- Headquarters
- Alameda, CA
- Employees
- 4,700
- IPO year
- 2015
- Website
- penumbrainc.com
Financial highlights
Full financialsIn fiscal 2025, Penumbra generated $1.40 billion in revenue, up 17.5% from fiscal 2024, its 12th consecutive year of revenue growth. Net income was $177.7 million (+1168.1% year over year), for a net margin of 12.7% versus a median of 0.7% in the prior 5 years. Gross margin was 67.1% (up from 63.2%) and operating margin 13.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.40B | $1.19B | $1.06B | $847.13M | $747.59M |
| Growth | +17.50% | +12.86% | +24.95% | +13.32% | +33.40% |
| Net income | $177.69M | $14.01M | $90.95M | $-2.00M | $5.28M |
| EPS (diluted) | $4.52 | $0.36 | $2.32 | $-0.05 | $0.14 |
Analyst forecast
ForecastConsensus (16 analysts)
hold
Avg. price target
$361.58+14.30%
- Strong buy 1
- Buy 2
- Hold 13
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $0.88 vs —
Penumbra peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SNNSmith & Nephew SNATS Inc. | 26.89 | +0.07% | $11.25B | vs PEN |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs PEN |
| TXG10x Genomics Inc. Class A | 76.10 | -5.65% | $9.92B | vs PEN |
| GMEDGlobus Medical Inc. Class A | 73.75 | -3.51% | $9.90B | vs PEN |
| BIOBio-Rad Laboratories Inc. Class A | 367.92 | -0.25% | $9.84B | vs PEN |
| PODDInsulet Corporation | 134.36 | -0.27% | $9.32B | vs PEN |
| BRKRBruker Corporation | 59.72 | -1.29% | $9.10B | vs PEN |
| ZBHZimmer Biomet Holdings Inc. | 88.49 | -1.33% | $16.88B | vs PEN |
Indexes, lists and sector
Appears in lists
Penumbra stock FAQ
What is Penumbra's stock price today?
PEN last traded at $316.35 as of Oct 7, 4:00 PM EDT, down 0.22% on the day. Prices are delayed at least 15 minutes.
When is Penumbra's next earnings date?
Penumbra is expected to report earnings on Wednesday, November 4, 2026.
What is PEN's P/E ratio?
PEN trades at a trailing P/E ratio of 77.73 and a forward P/E of 51.59, compared with a median of 21.5 for its closest peers.
Who is Penumbra's CEO?
Mr. Adam Elsesser J.D. is the chief executive officer of Penumbra Inc., which has about 4,700 employees.
What is the PEN 52-week high?
The 52-week high for PEN is $362.41 and the 52-week low is $221.26. The stock is currently 12.7% below its high.